Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian T...
Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9826 0399
Fax: 61 3 9824 0083
Address:
Level 9, 505 Little Collins Street, Melbourne, Australia
